The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index; 8 of the 18 sources its claims cite were checked for support.
Teclistamab in Relapsed or Refractory Multiple Myeloma
Open accessAbstract
BACKGROUND: Teclistamab is a T-cell-redirecting bispecific antibody that targets both CD3 expressed on the surface of T cells and B-cell maturation antigen expressed on the surface of myeloma cells. In the phase 1 dose-defining portion of the study, teclistamab showed promising efficacy in patients with relapsed or refractory multiple myeloma. METHODS: In this phase 1-2 study, we enrolled patients who had relapsed or refractory myeloma after at least three therapy lines, including triple-class exposure to an immunomodulatory drug, a proteasome inhibitor, and an anti-CD38 antibody. Patients received a weekly subcutaneous injection of teclistamab (at a dose of 1.5 mg per kilogram of body weight) after receiving step-up doses of 0.06 mg and 0.3 mg per kilogram. The primary end point was the overall response (partial response or better). RESULTS: Among 165 patients who received teclistamab, 77.6% had triple-class refractory disease (median, five previous therapy lines). With a median follow-up of 14.1 months, the overall response rate was 63.0%, with 65 patients (39.4%) having a complete response or better. A total of 44 patients (26.7%) were found to have no minimal residual disease (MRD); the MRD-negativity rate among the patients with a complete response or better was 46%. The median duration of response was 18.4 months (95% confidence interval [CI], 14.9 to not estimable). The median duration of progression-free survival was 11.3 months (95% CI, 8.8 to 17.1). Common adverse events included cytokine release syndrome (in 72.1% of the patients; grade 3, 0.6%; no grade 4), neutropenia (in 70.9%; grade 3 or 4, 64.2%), anemia (in 52.1%; grade 3 or 4, 37.0%), and thrombocytopenia (in 40.0%; grade 3 or 4, 21.2%). Infections were frequent (in 76.4%; grade 3 or 4, 44.8%). Neurotoxic events occurred in 24 patients (14.5%), including immune effector cell-associated neurotoxicity syndrome in 5 patients (3.0%; all grade 1 or 2). CONCLUSIONS: Teclistamab resulted in a high rate of deep and durable response in patients with triple-class-exposed relapsed or refractory multiple myeloma. Cytopenias and infections were common; toxic effects that were consistent with T-cell redirection were mostly grade 1 or 2. (Funded by Janssen Research and Development; MajesTEC-1 ClinicalTrials.gov numbers, NCT03145181 and NCT04557098.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
39 Own result · 14 Own interpretation · 9 Own method · 6 No full text of the sources · 2 Supported · 2 Supported so far · 2 Partly supported · accuracy not yet measured
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“In contrast, higher-grade cytokine release syndrome and neurotoxic events have been described after CAR-T administration in patients with multiple myeloma.6,8”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > DISCUSSION
What the sources say
- Supportedcites [6] source
Table 2 reports grade 3 or higher cytokine release syndrome in 7 of 128 patients and grade 3 neurotoxic effects in 4 of 128 after ide-cel infusion. The Methods identify the treated population as patients with relapsed and refractory multiple myeloma. (LLM, conf=0.93)
- Not checked — no full text of the sourcecites [8] source
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Among 165 patients who received teclistamab, 77.6% had triple-class refractory disease (median, five previous therapy lines).”
- Also stated in: § PATIENTS · plain
“Before study entry, 148 patients (89.7%) had resistance to the previous line of therapy, 128 (77.6%) had triple-class refractory disease, and 50 (30.3%) had penta-drug refractory disease.”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > Abstract > RESULTS
plainn = 165- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § PATIENTS · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Responses occurred in 104 of 165 patients (63.0%; 95% confidence interval [CI], 55.2 to 70.4).”
- Also stated in: § RESULTS · plain
“the overall response rate was 63.0%”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > RESULTS > EFFICACY
plainn = 165- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § RESULTS · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The median duration of progression-free survival was 11.3 months (95% CI, 8.8 to 17.1)”
- Also stated in: § RESULTS · plain
“The median duration of progression-free survival was 11.3 months (95% CI, 8.8 to 17.1).”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > Abstract > RESULTS
plainn = 165- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § RESULTS · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The Kaplan–Meier estimate of maintenance of response for at least 12 months was 68.5% (95% CI, 57.7 to 77.1).”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > RESULTS > EFFICACY
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Otherwise, response rates were consistent across most clinically relevant subgroups, including patients with high-risk cytogenetic abnormalities and those with penta-drug refractory disease (Fig. S2).”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > RESULTS > EFFICACY
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Hypogammaglobulinemia occurred in 123 patients (74.5%) as determined by means of adverse-event reporting, laboratory analyses (IgG level, <500 mg per deciliter), or both”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > RESULTS > SAFETY
plainn = 123- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Among the 65 patients who had a complete response or better, 30 (46%) had no minimal residual disease (Table S4).”
- Also stated in: § RESULTS · plain
“the MRD-negativity rate among the patients with a complete response or better was 46%”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > RESULTS > EFFICACY
plainn = 65- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § RESULTS · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Negativity for minimal residual disease (at a threshold of 10−5) was reported in 44 patients (26.7%; 95% CI, 20.1 to 34.1).”
- Also stated in: § RESULTS · plain
“A total of 44 patients (26.7%) were found to have no minimal residual disease (MRD)”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > RESULTS > EFFICACY
plainn = 44- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § RESULTS · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“a complete response or better occurred in 65 (39.4%)”
- Also stated in: § RESULTS · plain
“65 patients (39.4%) having a complete response or better”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > RESULTS > EFFICACY
plainn = 65- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § RESULTS · plain
- It may state two separate claims as one. 31
- Probably not a substantial claim. 12
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“CAR-T therapy requires that patients have access to specialized care centers and can wait the minimum 4-week period for production, which can result in attrition rates of approximately 10 to 15%,6-8”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > DISCUSSION
What the sources say
- Partly supportedcites [6] sourceExperimental — accuracy not yet measured
The Patients section (page not available) reports that 12 of 140 enrolled patients discontinued before ide-cel infusion, an attrition rate of about 8.6%, and that some patients received bridging therapy during manufacturing. It does not establish a minimum four-week production period, a requirement for access to specialized care centers, or that waiting caused the discontinuations. (LLM, conf=0.85)
- Partly supportedcites [7] sourceExperimental — accuracy not yet measured
The Discussion and future perspectives section (page unavailable) says CAR T-cell treatment involves a specialized center and that manufacturing takes several days to weeks, during which disease may progress. It does not establish a minimum four-week production period or an attrition rate of approximately 10–15%. (LLM, conf=0.88)
- Not checked — no full text of the sourcecites [8] source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Partly supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Such absence of minimal residual disease has been associated with improved overall survival and progression-free survival in patients with myeloma.14-16”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > DISCUSSION
What the sources say
- Not checked — no full text of the sourcecites [14] source
- Supportedcites [15] source
The Introduction states that MRD-negative status is associated with improved progression-free survival (PFS) and overall survival (OS). The Discussion likewise reports prior multiple-myeloma findings for both outcomes; the paper's own OS data were immature, but the claim does not attribute an OS result to this study's analysis. (LLM, conf=0.94)
- Supportedcites [16] source
The Discussion states that MRD negativity is associated with improved survival in both newly diagnosed and relapsed/refractory myeloma. The Introduction links MRD negativity with prolonged progression-free and overall survival, supporting both endpoints in the claim. (LLM, conf=0.90)
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
Every source the paper cites for this claim was checked and supports it.
In the paper
“Adverse events were graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (version 4.03), except for cytokine release syndrome (Table S2) and immune effector cell–associated neurotoxicity syndrome, which were graded according to the criteria of the American Society for Transplantation and Cellular Therapy.12”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > METHODS > END POINTS AND ASSESSMENTS
What the sources say
- Supportedcites [12] source
The citation supports the exception for CRS and ICANS: the paper sets out consensus grading criteria for both in its ‘Consensus on CRS Grading (Table 2)’ and ‘Consensus on ICANS Grading for Adults’ sections (page not available). The citing study’s choice to grade its other adverse events using CTCAE v4.03 is not attributed to this source. (LLM, conf=0.93)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The primary end point of the phase 2 study was the overall response rate, which was defined as a partial response or better according to the criteria of the International Myeloma Working Group, as assessed by an independent review committee”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > METHODS > END POINTS AND ASSESSMENTS
What the sources say
- Partly supportedcites [10] sourceExperimental — accuracy not yet measured
The Response criteria section recommends IMWG criteria for clinical trials and endorses the IMWG definition of partial response; the Minimal response section also distinguishes partial response or better from minimal response. The paper does not establish that overall response rate was the primary endpoint of the particular phase 2 study or that an independent review committee assessed it (pages not provided). (LLM, conf=0.87)
- Not checked — no full text of the sourcecites [11] source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Of the 19 deaths due to adverse events in our study, 12 were attributed to Covid-19, which was consistent with the higher mortality observed from Covid-19 in patients with hematologic cancers during this time frame.24”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > DISCUSSION
What the sources say
- Supportedcites [24] source
The citation supports the background comparison, not the citing authors’ own count of 12 COVID-19 deaths among 19 adverse-event deaths. The Discussion reports high COVID-19 mortality in patients with hematologic malignancies and says it was substantially higher than in the general population, while cautioning that the estimate may be elevated by the large proportion of hospitalized patients. (LLM, conf=0.92)
plaincorrelationaln = 19- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“median, five previous therapy lines”
- Also stated in: § PATIENTS · plain
“Patients had received a median of 5 previous lines of therapy (range, 2 to 14)”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > Abstract > RESULTS
plainn = 165- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
- Also stated in: § PATIENTS · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Teclistamab exposure was sustained over the predetermined target level (6 μg per milliliter, based on the upper boundary of an experimentally determined range of the 90% maximal effective concentration) with a low peak-to-trough ratio (Fig. S3).”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > RESULTS > PHARMACOKINETICS, IMMUNOGENICITY, AND BIOMARKERS
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Cytokine release syndrome occurred in 119 patients (72.1%). Most events occurred after step-up and cycle 1 doses, with 6 patients (3.6%) having cytokine release syndrome in cycle 2 or later. Most events of cytokine release syndrome were grade 1 or 2 in severity and fully resolved, except for one grade 3 event”
- Also stated in: § RESULTS · plain
“cytokine release syndrome (in 72.1% of the patients; grade 3, 0.6%; no grade 4)”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > RESULTS > SAFETY
plainn = 119- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Also stated in: § RESULTS · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Response rates were lower in patients with extramedullary disease, stage III disease, and at least 60% marrow replacement by plasma cells and were higher in those who had received no more than three previous lines of therapy.”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > RESULTS > EFFICACY
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“thrombocytopenia (in 66 [40.0%])”
- Also stated in: § RESULTS · plain
“thrombocytopenia (in 40.0%; grade 3 or 4, 21.2%)”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > RESULTS > SAFETY
plainn = 66- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Also stated in: § RESULTS · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“A total of 68 patients (41.2%) died, with most deaths (41) attributed to progressive disease (Table S9). Nineteen patients died from adverse events, including 12 deaths from coronavirus disease 2019 (Covid-19). Five deaths were considered by investigators to be related to teclistamab”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > RESULTS > SAFETY
plaindirectn = 68- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In addition, reductions in soluble BCMA levels occurred during the first 4 cycles of treatment in 63 of 72 evaluable patients (88%) who had a partial response or better, whereas all the evaluable patients who did not have a response (9 of 9 patients) had increased levels of soluble BCMA.”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > RESULTS > PHARMACOKINETICS, IMMUNOGENICITY, AND BIOMARKERS
plaincorrelationaln = 72- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“A total of 98 patients (59.4%) received at least 6 months of teclistamab treatment, and 79 patients (47.9%) received at least 9 months of treatment.”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > RESULTS > PATIENTS
plainn = 98- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“All 165 patients reported having an adverse event (Table 2 and Table S5), which were grade 3 or 4 in 156 patients (94.5%).”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > RESULTS > SAFETY
plainn = 165- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Five patients had a total of 9 events of immune effector cell–associated neurotoxicity syndrome, all either grade 1 or 2. Of these 9 events, 7 were concurrent with cytokine release syndrome, and all 9 events resolved without discontinuation or dose reduction.”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > RESULTS > SAFETY
plaincorrelationaln = 5- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“neutropenia (in 117 patients [70.9%])”
- Also stated in: § RESULTS · plain
“neutropenia (in 70.9%; grade 3 or 4, 64.2%)”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > RESULTS > SAFETY
plainn = 117- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Also stated in: § RESULTS · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Injection-site reactions were reported in 60 patients (36.4%); all such events were grade 1 or 2.”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > RESULTS > SAFETY
plainn = 60- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The median time until the onset of cytokine release syndrome was 2 days (range, 1 to 6) after the most recent dose, and the median duration was 2 days (range, 1 to 9).”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > RESULTS > SAFETY
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Investigator-assessed neurotoxic events, including immune effector cell–associated neurotoxicity syndrome, were reported in 24 patients (14.5%).”
- Also stated in: § RESULTS · plain
“Neurotoxic events occurred in 24 patients (14.5%), including immune effector cell–associated neurotoxicity syndrome in 5 patients (3.0%; all grade 1 or 2).”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > RESULTS > SAFETY
plainn = 24- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Also stated in: § RESULTS · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“anemia (in 86 [52.1%])”
- Also stated in: § RESULTS · plain
“anemia (in 52.1%; grade 3 or 4, 37.0%)”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > RESULTS > SAFETY
plainn = 86- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Also stated in: § RESULTS · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The median time until the first response was 1.2 months (range, 0.2 to 5.5), and the median time until a best response was 3.8 months (range, 1.1 to 16.8).”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > RESULTS > EFFICACY
plainn = 165- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“One patient had a dose reduction during cycle 21 because of recurrent neutropenia, and 104 patients (63.0%) skipped a dose because of adverse events. Two patients discontinued teclistamab because of adverse events (grade 3 adenoviral pneumonia and grade 4 progressive multifocal leukoencephalopathy).”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > RESULTS > SAFETY
plaindirectn = 104- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“As of March 16, 2022, 70 patients (42.4%) were continuing to receive treatment (Fig. S1), with a median treatment duration of 8.5 months (range, 0.2 to 24.4).”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > RESULTS > PATIENTS
plainn = 70- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Infections occurred in 126 patients (76.4%); 74 patients (44.8%) had grade 3 or 4 infections.”
- Also stated in: § RESULTS · plain
“Infections were frequent (in 76.4%; grade 3 or 4, 44.8%).”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > RESULTS > SAFETY
plainn = 126- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Also stated in: § RESULTS · plain
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The overall depth of response was highlighted by the observation that 26.7% of the patients were found to have no minimal residual disease at a sensitivity level of 10−5; these patients made up 82% of those in whom minimal residual disease could be evaluated.”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > DISCUSSION
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Cytopenias and infections were common; toxic effects that were consistent with T-cell redirection were mostly grade 1 or 2.”
- Also stated in: § DISCUSSION · plain
“Toxic effects were also common but were mainly of low grade and reversible.”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > Abstract > CONCLUSIONS
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Also stated in: § DISCUSSION · plain
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“The sponsor established a safety evaluation team to monitor patient safety throughout the phase 1 study. In phase 2, safety was monitored through continuous review by the sponsor.”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > METHODS > STUDY OVERSIGHT
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In addition, subgroup analyses suggest that patients who have received no more than three previous therapy lines may have a better response rate than those who have received more than three therapies, a finding that supports the use of teclistamab in earlier therapy lines (although the confidence intervals for this finding are wide).”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > DISCUSSION
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“Teclistamab redirects CD3+ T cells to BCMA+ myeloma cells, resulting in T-cell activation and subsequent lysis and death of BCMA+ cells.18”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > DISCUSSION
What the sources say
- Not checked — no full text of the sourcecites [18] source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“The study was conducted in accordance with the principles of the Declaration of Helsinki and the Good Clinical Practice guidelines of the International Council for Harmonisation.”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > METHODS > STUDY OVERSIGHT
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Toxic effects were also common but were mainly of low grade and reversible.”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > DISCUSSION
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The median relative dose intensity was high, and dose reductions and discontinuations owing to adverse events were infrequent.”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > DISCUSSION
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“The safety and efficacy populations for this analysis included all the patients who had received at least one dose of teclistamab at the recommended phase 2 dose in phase 1 or phase 2 as of September 7, 2021.”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > METHODS > STATISTICAL ANALYSIS
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Response rates were also compared across various prespecified subgroups, including those defined according to cytogenetic risk, refractory status, and number of previous lines of therapy.”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > METHODS > STATISTICAL ANALYSIS
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“For phase 2, we determined that a sample size of 100 patients would provide a power of at least 85% to establish an overall response rate of more than 30% at a one-sided significance level of 0.025, assuming an overall response rate of at least 45%.”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > METHODS > STATISTICAL ANALYSIS
hedgedn = 100- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim.
In the paper
“Adverse events in this phase 1–2 trial were common and included low-grade cytokine release syndrome and grade 3 or 4 cytopenia and infection in a patient population that has an increased susceptibility to infection due to the immunodeficiency associated with myeloma and immunosuppressive effects of previous myeloma therapies.23”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > DISCUSSION
What the sources say
- Not checked — no full text of the sourcecites [23] source
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Negativity for minimal residual disease was assessed by next-generation sequencing of DNA obtained from bone marrow aspirate (clonoSEQ assay, version 2.0 [Adaptive Biotechnologies]) with a threshold of 10−5 cells.”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > METHODS > END POINTS AND ASSESSMENTS
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“The study protocol, amendments, and relevant documents were approved by the local independent ethics committee or institutional review board at each study site. All the patients provided written informed consent.”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > METHODS > STUDY OVERSIGHT
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“All the authors affirm that the trial was conducted in accordance with the study protocol and vouch for the accuracy and completeness of the data.”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > METHODS > STUDY OVERSIGHT
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
The paper relies on this without support.
Teclistamab is readily available.
“Teclistamab is readily available and has been associated with rapid onset of response after a median of approximately 1 month of treatment.”
The paper relies on this without support.
No CD3-redirecting therapy has been approved for the treatment of myeloma.
“Although clinical proof of concept has been obtained for other CD3-redirection platforms in other indications,19-21 no CD3-redirecting therapy has been approved for the treatment of myeloma.”
The paper relies on this without support.
Cross-trial comparisons are challenging to interpret owing to differences in study design and patient populations.
“Although cross-trial comparisons are challenging to interpret owing to differences in study design and patient populations, the response rates observed with teclistamab (63%) compare favorably with those of belantamab mafodotin”
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“Two BCMA-targeting bispecific antibodies, teclistamab and elranatamab, have been approved for use in patients with relapsed myeloma who have received at least 4 prior regimens.91,92”
From Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management (2024) · cites this paper as [91]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“A number of BCMA-directed therapies, including belantamab mafodotin, idecabtagene vicleucel (ide-cel), ciltacabtagene autoleucel (cilta-cel) and teclistamab, have shown efficacy in clinical trials and are approved for the treatment of relapsed or refractory multiple myeloma4–9.”
From Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results (2023) · cites this paper as [4]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Similarly, patients with advanced disease stage (R-ISS stage III) have consistently shown poorer outcomes irrespective of the therapy received4–6,19–22.”
From Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results (2023) · cites this paper as [4]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In comparison to other BCMA-targeted T-cell-redirecting therapies, the rate of hematologic AEs with elranatamab was similar or lower after a similar follow-up4–6.”
From Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results (2023) · cites this paper as [4]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“and favorable to the BCMA-targeting antibody–drug conjugate, belantamab mafodotin (ORR 32%, median DOR 11.0 months and median PFS 2.8 months) after a median follow-up of 12.4 months4,9,19,23.”
From Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results (2023) · cites this paper as [4]
Experimental — accuracy not yet measured
The cited source says what the claim attributes to it.
In the citing paper
“Teclistamab and elranatamab are bispecific antibodies produce an immunotherapeutic effect by binding to BCMA on myeloma cells on one arm and CD3 on T cells with the other.91,92”
From Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management (2024) · cites this paper as [91]
The cited source says what the claim attributes to it.
In the citing paper
“The primary endpoint in phase 2 was overall response rate per IMWG criteria,11 based on independent committee review, which was defined as the proportion of patients who had a partial response or better.”
From Safety and activity of talquetamab in patients with relapsed or refractory multiple myeloma (MonumenTAL-1): a multicentre, open-label, phase 1-2 study. (2025) · cites this paper as [11]
The cited source says what the claim attributes to it.
In the citing paper
“Teclistamab, a bispecific antibody targeting CD3×BCMA,6 demonstrated deep and durable responses in heavily pretreated RRMM in the phase 1/2 MajesTEC-1 study.7,8”
From Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma (2026) · cites this paper as [8]
The cited source says what the claim attributes to it.
In the citing paper
“Cytokine release syndrome incidence was lower than that observed with teclistamab monotherapy in MajesTEC-1 (60.1% vs. 72.1%, respectively),8 with most events being grade 1 and occurring during the step-up dosing schedule.”
From Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma (2026) · cites this paper as [8]
The cited source says what the claim attributes to it.
In the citing paper
“In this trial, 165 RRMM patients were treated with Teclistamab, and the following key outcomes were observed 63.0% ORR, 58.8% VGPR, and 39.4% CR. These results demonstrate the significant clinical activity of Teclistamab in RRMM patients who have received multiple prior lines of therapy. The high ORR, VGPR rate, and CR rate indicate substantial anti-myeloma activity of Teclistamab. Additionally, t”
From Multiple myeloma: signaling pathways and targeted therapy (2024) · cites this paper as [209]
The cited source says what the claim attributes to it.
In the citing paper
“The lower response rate observed in patients with extramedullary disease reflects the historically poor prognosis in this subgroup and has also been observed with other anti-BCMA-targeted agents such as belantamab mafodotin and teclistamab4,19.”
From Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results (2023) · cites this paper as [4]
Citations
Cites
Lee, D. W., Santomasso, B. D., Locke, F. L., Ghobadi, A., Turtle, C. J., Brudno, J. N., Maus, M. V., Park, J. H., Mead, E., Pavletic, S., et al. (2019) · Biology of Blood and Marrow Transplantation · doi:10.1016/j.bbmt.2018.12.758 · Cited by 3,675
Kumar, S., Paiva, B., Anderson, K. C., Durie, B., Landgren, O., Moreau, P., Munshi, N., Lonial, S., Bladé, J., Mateos, M.-V., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30206-6 · Cited by 3,061
Self-citationIdecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma.
Munshi, N. C., Anderson, L. D., Shah, N., Madduri, D., Berdeja, J., Lonial, S., Raje, N., Lin, Y., Siegel, D., Oriol, A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2024850 · Cited by 2,560
Self-citationBerdeja, J. G., Madduri, D., Usmani, S. Z., Jakubowiak, A., Agha, M., Cohen, A. D., Stewart, A. K., Hari, P., Htut, M., Lesokhin, A., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00933-8 · Cited by 1,756
Self-citationRajkumar, S. V., Harousseau, J.-L., Durie, B., Anderson, K. C., Dimopoulos, M., Kyle, R., Blade, J., Richardson, P., Orlowski, R., Siegel, D., et al. (2011) · Blood · doi:10.1182/blood-2010-10-299487 · Cited by 1,036
Self-citationMultiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†
Dimopoulos, M. A., Moreau, P., Terpos, E., Mateos, M. V., Zweegman, S., Cook, G., Delforge, M., Hájek, R., Schjesvold, F., Cavo, M., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2020.11.014 · Cited by 900
Self-citationLonial, S., Lee, H. C., Badros, A., Trudel, S., Nooka, A. K., Chari, A., Abdallah, A.-O., Callander, N., Lendvai, N., Sborov, D., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30788-0 · Cited by 812
Self-citationVijenthira, A., Gong, I. Y., Fox, T. A., Booth, S., Cook, G., Fattizzo, B., Martín-Moro, F., Razanamahery, J., Riches, J. C., Zwicker, J., et al. (2020) · Blood · doi:10.1182/blood.2020008824 · Cited by 625
Shah, N., Chari, A., Scott, E., Mezzi, K., & Usmani, S. Z. (2020) · Leukemia · doi:10.1038/s41375-020-0734-z · Cited by 490
Self-citationBispecific T‐cell engagers for cancer immunotherapy
Huehls, A. M., Coupet, T. A., & Sentman, C. L. (2014) · Immunology and Cell Biology · doi:10.1038/icb.2014.93 · Cited by 478
Cited by
Sorted by citations
Items 701–800 of 1,251
Novel pretransplant desensitization strategies in heart transplantation
Coutance, G., Chong, A. S., & Habal, M. V. (2025) · JHLT Open · doi:10.1016/j.jhlto.2025.100242 · Cited by 4
Current advances in bispecific T cell–engaging therapies
Ansah, E. O., Ansong, B., & Kyei, F. (2025) · Advances in Medical Pharmaceutical and Dental Research · doi:10.21622/ampdr.2025.05.1.1222 · Cited by 3
CAR-T cell therapy in myeloma: hopes and hurdles
Harousseau, J. L. (2023) · Blood Science · doi:10.1097/bs9.0000000000000148 · Cited by 3
GPRC5D: The Next Frontier for Immunotherapy in Multiple Myeloma
Bhutani, M., & Usmani, S. (2023) · The Hematologist · doi:10.1182/hem.v20.1.202314 · Cited by 3
Self-citationEditorial: T-cell directed therapies in multiple myeloma
Richter, J. R., Anderson, L. D., Ramasamy, K., & Rossi, A. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1206475 · Cited by 3
New Enhancing Oncology Model builds on knowledge from the OCM
Staggs, S. (2022) · The American Journal of Managed Care · doi:10.37765/ajmc.2022.89229 · Cited by 2
Richter, J. R. (2023) · British Journal of Haematology · doi:10.1111/bjh.19267 · Cited by 2
Epcoritamab in B-cell malignancies: current status and prospects
Molica, S., Rossi, M., & Allsup, D. J. (2024) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2024.2310148 · Cited by 2
Popat, R., Basu, S., Henshaw, S., Karunanithi, K., Ramasamy, K., Singh, I., Tailor, A., WALKER, I. C., Warren, T., Ali, N., et al. (2024) · eJHaem · doi:10.1002/jha2.1038 · Cited by 2
Self-citationKarp, S., Trautmann‐Grill, K., Warncke, P., Zolnowski, D., Röllig, C., Pannach, M., Zinn, J., Kroschinsky, F., Morgner, A., Bonin, M. V., et al. (2025) · Annals of Hematology · doi:10.1007/s00277-025-06262-9 · Cited by 2
Danis, R., Bujarski, S., Yashar, D., Dosso, A. D., Moore, J., Mettias, S., & Berenson, J. R. (2025) · Leukemia research : a Forum for Studies on Leukemia and Normal Hemopoiesis · doi:10.1016/j.leukres.2025.107677 · Cited by 3
Functional Cure as a New Concept of Therapy for Multiple Myeloma
Семочкин, С. В. (2025) · Clinical oncohematology · doi:10.21320/2500-2139-2025-18-2-105-120 · Cited by 2
Chinese expert consensus on the application of intravenous immunoglobulin in hematological diseases
Guo, Z. K., Zhu, J., Wang, J., Wang, L., Tang, F., Huang, H., Xia, Z., Liu, L., Wang, D., Zhong, N., et al. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1544025 · Cited by 2
“…such as autologous HSCT, bispecific antibodies, CAR-T cell therapy, cytotoxic chemotherapy drugs, proteasome inhibitors, anti-CD38 monoclonal antibodies, glucocorticoids, etc. 75% of patients receiving bispecific antibody therapy in the MajesTEC-1 study developed hypogammaglobulinemia (52).”
Ayyappan, S. R., Larsen, J. T., Sanchez, J. F., & Krishnan, A. Y. (2025) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2025.04.006 · Cited by 2
Self-citationShrestha, A., Kumar, A. K. T. A., Pandey, S., et al. (2025) · Frontiers in Hematology · doi:10.3389/frhem.2025.1547209 · Cited by 2
Kulig, P., Rałowiec, A., Baumert, B., & Machaliński, B. (2025) · Clinical and Experimental Medicine · doi:10.1007/s10238-025-01728-6 · Cited by 2
“The most important are bispecific antibodies [21], drug-anti-body conjugates [33], CAR-T cells and CAR-NK cells [22].”
Revolutions at the frontline of multiple myeloma treatment: lessons and challenges to finding a cure
Kort, J., Rivera, A., Senigarapu, S., & Driscoll, J. J. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1578529 · Cited by 2
Rosenberg, M. C., Scarpetti, L., Morgan, G. J., & Davies, F. E. (2025) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2025.06.013 · Cited by 2
Collo, G. D., Grusanovic, S., Rasouli, M., van Hoven-Beijen, A., Mueller, Y. M., van der Sande, Z.-L., van Hagen, M., Cornelissen, J. J., He, Y., Wang, Y., et al. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2025-011888 · Cited by 2
Mouhieddine, T. H., Ghobrial, I. M., & Nadeem, O. (2025) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2025.101641 · Cited by 3
Szymczyk, A., Drozd-Sokolowska, J. E., & Hus, I. (2025) · Cancers · doi:10.3390/cancers17152426 · Cited by 2
“In the pivotal MajecTEC-1 trial [53], treatment with teclistamab (BCMA-targeting BsAB) was associated with any-grade infectious complications in 78%, and grade 3 or higher in 52% of patients.”
Bispecific T-cell engager therapy for multiple myeloma
Cirstea, D. D., Puliafito, B. R., Kim, B. E., Lei, M., & Raje, N. S. (2025) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2025.101649 · Cited by 2
The silent signals: emerging safety concerns in bispecific antibody therapy for multiple myeloma
Zhou, X., Luo, E., Chen, W., Deng, Y., Wu, B., Jiang, X., Zhang, K., & Lai, F. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1593405 · Cited by 2
“After a median 14.1 months follow-up, the overall response rate (ORR) was reported at 63.0%, and the median length of response was 18.4 months (9).”
InfluentialManagement of relapsed refractory multiple myeloma: Evidence-based guide to community oncologists
Mushtaq, A. H., Cheema, A. Y., Ali, H. M., Shatnawi, Y., Ashruf, O. S., Ahmad, E. N., Lytvynova, O., Munir, M., Asif, M. A., Ahmad, M., et al. (2025) · Blood Reviews · doi:10.1016/j.blre.2025.101339 · Cited by 4
Bahlis, N. J., Zonder, J. A., Karlin, L., Plesner, T., París, L., Wróbel, T., Hungria, V., Besemer, B., Crusoé, E., Silkjær, T., et al. (2025) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2025.2561117 · Cited by 3
Self-citationA Case Report Supporting the Use of Teclistamab in Multiple Myeloma With CNS Involvement
Blackman, J., Blackman, J., Blackman, J. T., et al. (2025) · Case Reports in Hematology · doi:10.1155/crh/8425047 · Cited by 2
“At this 2 Case Reports in Hematology time, there is no available information describing its ability to permeate the blood–brain barrier, but there was mild response in patients with extramedullary disease suggesting some penetration [8].”
Bilbao, I., Ansón, M., Villar, S., Pineda, I., Gárriz, L., Pina‐Sánchez, M., Tamariz‐Amador, L., Rodríguez‐Otero, P., Yuste, J. R., & del Pozo, J. L. (2025) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofaf672 · Cited by 2
Saga of MCL1 inhibitors in multiple myeloma
Nelson, E., Telang, S. P., Budak-Alpdoǧan, T., Jonnalagadda, S. C., Srivastava, S. K., & Pandey, M. K. (2025) · Biochemical Pharmacology · doi:10.1016/j.bcp.2025.117532 · Cited by 3
Dermatologic Adverse Effects With Elranatamab Mimicking Talquetamab
Hammami, M. B., Haney, S., DeAvila, D., Fadul, J., Simonelli, C. E., Seitzler, S., Ravichandran, S., Alsina, M., Blue, B. J., Grajales-Cruz, A. F., et al. (2025) · American Journal of Hematology · doi:10.1002/ajh.70130 · Cited by 2
“To the Editor, Treatment options for relapsed/refractory multiple myeloma (RRMM) have recently expanded with the approval of bispecific antibodies (BsAbs) [1–4].”
Advances in immune microenvironment profiling during multiple myeloma progression and therapy
Bai, J., Nishimura, N., & Kawano, Y. (2025) · International Journal of Hematology · doi:10.1007/s12185-025-04110-0 · Cited by 4
Somboonpatarakun, C., Phanthaphol, N., Suwanchiwasiri, K., et al. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.118806 · Cited by 2
Rizzello, I., Sacchetti, I., Barbato, S., Solli, V., Stefanoni, P., Cani, L., Quaresima, M., Belotti, A., Sgherza, N., Gentile, M., et al. (2025) · Clinical and Experimental Medicine · doi:10.1007/s10238-025-01956-w · Cited by 2
“The survival data observed in our retrospective analysis compare favorably with the mPFS of 14.8 months and mOS of 28.9 months reported in a collection of len-ref patients treated with daratumumab-containing combination in clinical trials [29].”
InfluentialAfrough, A., Dima, D., Razzo, B. M., Goel, U., Sannareddy, A., Pasvolsky, O., Vazquez-Martinez, M. A., Ferreri, C. J., Banerjee, R., Khouri, J., et al. (2025) · Blood Cancer Journal · doi:10.1038/s41408-025-01414-6 · Cited by 6
Self-citationFogel, L., Roney, P. C., Ahn, J., Aleman, A., Perez-Manon, F., Arias‐Orozco, N., Monteleone, G., Londono, K., Builes, K., Anand, P., et al. (2025) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2025.2592783 · Cited by 2
“Eligibility for MajesTEC-1, MagnetisMM-1, or MonumenTAL-1, respectively, was assessed according to published inclusion and exclusion criteria [5,7,8].”
InfluentialVoorhees, P. M., Kumar, S. K., Usmani, S. Z., Ye, J. C., Cohen, Y. C., Scott, E., Carson, R. L., Heuck, C. J., Gan, R. W., Ackerman, B., et al. (2025) · Annals of Hematology · doi:10.1007/s00277-025-06705-3 · Cited by 2
Self-citationZhang, Y., Lei, Y., Huang, Y., Gao, Y., Liu, R., Guo, K., Zhao, C., & Lei, M. (2025) · Molecular Biology Reports · doi:10.1007/s11033-025-11317-1 · Cited by 2
Mina, R., Antonioli, E., Barilà, G., Bolli, N., Botta, C., Furlan, A., Liberatore, C., Martello, M., Móre, S. M. C., Oliva, S., et al. (2025) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2025.12.016 · Cited by 3
Martin, T. G., Mateos, M., Yi, J. H., van de Donk, N. W. C. J., Cai, Z., Fu, W., Garfall, A. L., Iida, S., Jung, S., Kuroda, Y., et al. (2026) · Cancer · doi:10.1002/cncr.70237 · Cited by 2
“8,18,19 The detailed study design, oversight, eligibility criteria, assessment methods, and statistical analyses for all these three studies have been previously described and published.”
Self-citationRoy, P. G., Gogia, A., Anwar, Z., Mukherjee, S., & Anwer, F. (2026) · JCO Oncology Practice · doi:10.1200/op-25-00947 · Cited by 2
Frenking, J. H., Riedhammer, C., Hielscher, T., Schaefers, C., Leypoldt, L. B., Harzer, M., Sedloev, D. N., Landrin, V., Kehl, N., Friedrich, M., et al. (2026) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-25-0062 · Cited by 2
Autologous Stem Cell Transplantation in Multiple Myeloma: Is It Still the Gold Standard?
Dohadwala, T. K., Ghazal, J. F., Nadar, S., Vaishnav, R., Paduvagere, I., Cortiana, V., Park, C. H., & Leyfman, Y. (2026) · ONCOLOGY · doi:10.46883/2026.25921059 · Cited by 3
Derman, B. A., Liu, J. J., Bouchard, N., Figg, L., LaPorte, J., Goorha, S., Pagan, K. A., Tandra, A., Varshavsky, A., Ko, G., et al. (2026) · Current Medical Research and Opinion · doi:10.1080/03007995.2026.2626367 · Cited by 3
“In the MajesTEC-1 trial, ICANS occurred in 3% of patients (all grade 1–2) while CRS occurred in 72% of patients, (all grade 1–2 except one patient experiencing a grade 3 event in the setting of an infection) 7 .”
Lowy, J. A., Rogers, M. F., Avigan, Z. M., Flores, M. S., Samuel, M., Rattu, M. A., & Richter, J. (2026) · Expert Review of Hematology · doi:10.1080/17474086.2026.2634283 · Cited by 2
“ORR was reported to be 63% in long-term follow-up, with 46% of patients achieving a complete response (CR) [27,39].”
InfluentialBorkowski, A., Giordano, U., Szlasa, W., et al. (2026) · Cancers · doi:10.3390/cancers18040686 · Cited by 2
“It was not permitted in MajesTEC-1 trial, while it was present in a subset of patients in the Freeman et horts (13% and 31%, respectively) [22,24,25].”
Tan, C. R., Usmani, S. Z., Derkach, A., Corraes, A. D. M. S., Parrondo, R. D., Ailawadhi, S., Asoori, S., Dave, M., Popat, R., Morjaria, O., et al. (2026) · Blood Advances · doi:10.1182/bloodadvances.2025019231 · Cited by 2
“5,7 These estimates are comparable to findings from a systematic review and meta-analysis of bsAbs for MM, which estimated NRM rates of 6.2%, primarily due to infections, particularly COVID-19, which was the leading cause of NRM. 25 Treatment-related T-cell activation, T-cell exhaustion, and…”
InfluentialSelf-citationWang, Y.-C., Li, P.-H., Lin, C., Su, Y., & Teng, C. J. (2026) · Targeted Oncology · doi:10.1007/s11523-026-01209-0 · Cited by 2
“For teclistamab, the median PFS was 11.3 months in the MajesTEC-1 study [8], comparable to the median TTNT of 12.3 months in our teclistamab cohort.”
InfluentialRamírez-Alvarado, A. G., Varela-Constantino, A. L., Gómez‐Almaguer, D., Ovilla-Martínez, R., Alvarado‐Ibarra, M., Pérez-Zincer, F., Ramos‐Peñafiel, C., Cruz, D., Solano-Genesta, M., López-Sánchez, M. D. C., et al. (2026) · European Journal Of Haematology · doi:10.1111/ejh.70176 · Cited by 2
Cardé, N. A. Q., Niu, J., Guo, Y., et al. (2026) · Targeted Oncology · doi:10.1007/s11523-026-01205-4 · Cited by 2
“Full details of the MajesTEC-1 study have been described previously [13, 14].”
Self-citationAl-Bazaz, M., Alsdorf, W. H., Leypoldt, L. B., Sonnemann, P., Schaefers, C., Artzenroth, J. C., Harzer, M., Kamili, A., Bartke, L., Cords, L., et al. (2026) · American Journal of Hematology · doi:10.1002/ajh.70297 · Cited by 2
“Chimeric antigen receptor (CAR) T-cells and bispecific antibodies targeting B-cell maturation antigen (BCMA) and, more recently, G protein–coupled receptor class C group 5 member D (GPRC5D), have demonstrated unprecedented efficacy in heavily pretreated patients [3–5].”
Zerbit, J., Fouquet, G., Detroit, M., Choquet, S., Garderet, L., Hermine, O., Cazelles, C., Frenzel, L., Mohty, M., de Wyngaert, Z. V., et al. (2026) · JCO oncology advances. · doi:10.1200/oa-25-00077 · Cited by 2
Kumamoto, T., Yoshihara, K., Samori, M., et al. (2026) · eJHaem · doi:10.1002/jha2.70282 · Cited by 2
Melflufen in Multiple Myeloma: Clinical Limitations, Biological Rationale, and Future Perspectives
Garibotto, M., Soncini, D., Lemoli, R. M., Cagnetta, A., & Cea, M. (2026) · Cancers · doi:10.3390/cancers18101551 · Cited by 2
“In clinical practice, the selection of melflufen should be weighed against available alternatives, including CELMoDs, bispecific antibodies, and CAR T-cell therapies, considering treatment availability, prior exposure, disease kinetics, and patient fitness [12,73–76].”
Zhou, D., Qi, Y., Ma, S., Sun, Q., Gu, W., Xia, J., Zhang, X., Chen, W., Cheng, H., Qi, K., et al. (2026) · Blood · doi:10.1182/blood.2026033506 · Cited by 4
Sperling, A. S., Derman, B. A., Nikiforow, S., Alonso, A., Ikegawa, S., Orwitz, N., Quinn, D. S., Pearson, D. E., 部德秀, Milanez‐Almeida, P., et al. (2026) · Science Translational Medicine · doi:10.1126/scitranslmed.adx1799 · Cited by 4
T-cell engagers in cancer immunotherapy: mechanisms, challenges, and future perspectives
Muthughavi, K., Khokhar, M., Jha, H. C., & Pandey, R. K. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1755512 · Cited by 2
Siegert, E., Phithak, E., Albach, F. N., Biesen, R., Drzeniek, N. M., Dzamukova, M. R., Haase, I., Søndergaard, K. H., Schleser, D., Fiebig, L., et al. (2026) · Annals of the Rheumatic Diseases · doi:10.1016/j.ard.2026.05.023 · Cited by 6
“…administered subcutaneously according to a step-up regimen identical to that approved for the treatment of relapsed and refractory multiple myeloma [22], with the target dose of 1.5 mg/kg being administered 2 to 4 times in all patients (see Supplementary Table S1 for details); median cumulative…”
InfluentialBumma, N., Lee, H. C., Richter, J., Hoffman, J. E., Zonder, J., Fillbrunn, M., García-Horton, V., Zhou, Z.-Y., Xu, Y.-X., Burnett, H., et al. (2026) · Current Medical Research and Opinion · doi:10.1080/03007995.2026.2686032 · Cited by 2
Munir, M., Sayed, A., Lee, D. H., Ghazi, S. M., Houmsse, M. M., Badat, S., Moeed, A., Guha, A., Addison, D., & Epperla, N. (2026) · American Journal of Hematology · doi:10.1002/ajh.70449 · Cited by 2
T-Cell Engager–Mediated HLA Antibody Depletion before Kidney Transplantation
Schatzl, M., Mayer, K. A., Agis, H., et al. (2026) · New England Journal of Medicine · doi:10.1056/nejmc2603853 · Cited by 2
Teclistamab – myélome multiple en rechute ou réfractaire après au moins trois traitements antérieurs
Grand, S. L., & Karlin, L. (2023) · Bulletin du Cancer · doi:10.1016/j.bulcan.2023.01.021 · Cited by 2
Self-citationγ-Secretase inhibitors plus anti-BCMA chimeric antigen receptor T cells
Mussetti, A., & Sureda, A. (2023) · The Lancet Oncology · doi:10.1016/s1470-2045(23)00283-8 · Cited by 2
Benedetti, F., Stadlmayr, G., Stadlbauer, K., Rüker, F., & Wozniak‐Knopp, G. (2023) · Methods in molecular biology · doi:10.1007/978-1-0716-3279-6_9 · Cited by 2
Advances in the management of myeloma: an update
Meenaghan, T., Hayat, A., Walpole, G., & Dowling, M. (2023) · British Journal of Nursing · doi:10.12968/bjon.2023.32.17.s4 · Cited by 2
Favaloro, J., Bryant, C. E., Abadir, E., Gardiner, S. R., Yang, S., King, T., Nassif, N. T., Sedger, L. M., Boyle, R., Joshua, D., et al. (2023) · Haematologica · doi:10.3324/haematol.2023.283062 · Cited by 3
TO MARKET, TO MARKET–2022: MACROMOLECULAR THERAPEUTICS
Lim, S. A., Agard, N. J., Kelly, R. L., Bell, B. N., Chen, S.-J., Gram, A. M., Merritt, J. R., Moench, I., Pance, K., & Petojevic, T. (2023) · Medicinal chemistry reviews · doi:10.1021/mc-2023-vol58.ch25 · Cited by 2
Recent advances and future perspectives of T-cell engagers in lymphoid malignancies
Shirouchi, Y., & Maruyama, D. (2024) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyad186 · Cited by 2
Disparity in hematological malignancies: From patients to health care professionals
Chen, X., Shukla, M., & Fleur-Lominy, S. S. (2024) · Blood Reviews · doi:10.1016/j.blre.2024.101169 · Cited by 2
Frebel, K., Albring, J. C., Wohlgemuth, A., Schwöppe, C., Hailfinger, S., Lenz, G., & Stelljes, M. (2024) · Blood Advances · doi:10.1182/bloodadvances.2023011647 · Cited by 2
“51 Similar to other T-cell – mediated therapeutics, ~72% of patients experience CRS after receiving teclistamab.”
BackgroundYi, J. H., Park, S., Min, C., Eom, H., Byun, J. M., Koh, Y., Yoon, S., Lee, J. H., Jung, S., Lee, J., et al. (2024) · Annals of Hematology · doi:10.1007/s00277-024-05615-0 · Cited by 2
Hämatologische Neoplasien und solide Tumore
Ludwig, W.-D., Ganser, A., & Maschmeyer, G. (2023) · Springer eBooks · doi:10.1007/978-3-662-68371-2_5 · Cited by 2
Krzysiek, R., Bitoun, S., Belkhir, R., Hacein‐Bey‐Abina, S., & Xavier Mariette, A. (2024) · Haematologica · doi:10.3324/haematol.2023.284942 · Cited by 2
CADTH (2024) · Canadian Journal of Health Technologies · doi:10.51731/cjht.2024.884 · Cited by 2
Cohen, I., Vaxman, I., & Gertz, M. A. (2024) · Acta Haematologica · doi:10.1159/000539225 · Cited by 3
Schütt, J., Brinkert, K., Plis, A., Schenk, T., & Brioli, A. (2024) · Cancer Drug Resistance · doi:10.20517/cdr.2024.39 · Cited by 2
Advances in Diagnosis and Treatment of AL Cardiac Amyloidosis
Sapru, A. B., Mohammadi, M., Medvedova, E., et al. (2024) · Current Treatment Options in Cardiovascular Medicine · doi:10.1007/s11936-024-01049-z · Cited by 2
“Teclistamab is an FDA-approved BCMA BsAbs that has a 63% overall response almost 40% with complete response in patients with RRMM [46].”
The Role of Monoclonal Antibodies in the Treatment of Myeloma Kidney Disease
Derudas, D., & Chiriu, S. (2024) · Pharmaceuticals · doi:10.3390/ph17081029 · Cited by 3
“The MajesTEC-1 study, which evaluated the safety and efficacy of this bispecific antibody as a monotherapy for RRMM subjects, excluded patients with an estimated glomerular filtration rate <40 mL/min, and 73% of patients had an eGFR > 60 mL/min [52].”
Backgroundvan Voss, M. R. H., Molenaar, R. J., Korst, C. L. B. M., Bartelink, I. H., Baglio, S. R., Kruyswijk, S., de Ruijter, M. E. M., Zweegman, S., Kuipers, M. T., & van de Donk, N. W. C. J. (2024) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2024.2397436 · Cited by 2
Self-citationSabbah, M., Nguyen, S., Ouzegdouh, M., Choquet, S., Buob, D., Boffa, J. J., Cez, A., & Garderet, L. (2024) · American Journal of Case Reports · doi:10.12659/ajcr.944681 · Cited by 2
“Significant advances have been made in the treat-ment of MM with the arrival of proteasome inhibitors, immunomodulatory drugs (IMiDs), CD38-targeted therapy, and, more recently, anti-BCMA treatments [4], which have led to better response and survival.”
BackgroundSanchez, J., Claus, C., McIntyre, C., Tanos, T., Boehnke, A., Friberg, L. E., Jönsson, S., & Frances, N. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1472662 · Cited by 3
Infections during novel myeloma therapies
Liu, A. J., Slavin, M. A., Harrison, S. J., & Teh, B. W. (2024) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2024.2428819 · Cited by 2
“…BsAbs include teclistamab (BcMA), elranatamab (BMcA), talquetamab (GPRc5D), with overall response rates (ORR) of 63%, 64% and 74% respectively [6–8]. the antibody-drug conjugate (ADc) belantamab mafodotin is a humanized anti-BcMA monoclonal antibody (mAb) that is also being evaluated in early…”
InfluentialKlomberg, K. M., Gelderloos, M., Kooistra, H., Nijland, M., Huls, G. A., Roeloffzen, W. W. H., & Plattel, W. J. (2024) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2024.12.010 · Cited by 2
Lin, C., Wu, S., Liao, C.-H., Weng, R. R., & Lin, C.-M. (2025) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2024.2447141 · Cited by 2
Katodritou, E., Kastritis, E., Dalampira, D., Fotiou, D., Theodorakakou, F., Delimpasi, S., Spanoudakis, E., Ntanasis-Stathopoulos, I., Papadopoulou, T., Sevastoudi, A., et al. (2025) · Clinical Lymphoma, Myeloma & Leukemia · doi:10.1016/j.clml.2025.01.002 · Cited by 1
Monoclonal Antibodies in Relapsed-Refractory Multiple Myeloma
Sorgiovanni, I., Giudice, M. L. D., Galimberti, S., & Buda, G. (2025) · Pharmaceuticals · doi:10.3390/ph18020145 · Cited by 3
“The subsequent Phase 1–2 study confirmed that a once-weekly subcutaneous dose of teclistamab (1.5 mg/kg after tapering) induced deep and durable responses in patients with triple-classified RRMM, consistent with previous findings [71].”
InfluentialChari, A., Bal, S., Ailawadhi, S., Krishnan, A. Y., Patel, K. K., Berdeja, J. G., Garfall, A. L., Callander, N. S., Banerjee, R., Alsina, M., et al. (2025) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2025.03.008 · Cited by 2
Self-citationHolstein, S. A., Atrash, S., Mian, H. S., Dimopoulos, M. A., Schjesvold, F. H., Popat, R., Shah, N. N., Gatt, M. E., Gocke, C. B., Frenzel, L., et al. (2025) · Blood · doi:10.1182/blood.2024027873 · Cited by 3
Self-citationRelapsed/refractory multiple myeloma: standard of care management of patients in the Gulf region
Alhuraiji, A., Farsi, K. A., Mheidly, K., Elsabah, H., Cherif, H., Hamad, A. A., Marashi, M., Al-Hateeti, H., Osman, H. Y., & Mohty, M. (2025) · Clinical Hematology International · doi:10.46989/001c.137860 · Cited by 2
Jeremian, R., Sivachandran, S., Galati, M., Ramchatesingh, B., Rijal, H., Hanna, J., Netchiporouk, E., Chergui, M., Redpath, M., Setah, S. A., et al. (2025) · Molecular Oncology · doi:10.1002/1878-0261.70107 · Cited by 2
“BCMA targeted therapies including CAR-T and BiTEs have also been approved in multiple myeloma [51,54,55].”
Park, H., Robinson, J., Flanagan, C., Pawlyn, C., Jackson, G., & Jones, J. (2025) · Leukemia and Lymphoma · doi:10.1080/10428194.2025.2560085 · Cited by 2
“…group developed SPMs, whilst 3 patients in Bite group developed SPMs. Pivotal trials that led to the regulatory approval of bispecific antibodies, including Majestec-1 (Nct03145181, Nct04557098), MonumentAl-1 (Nct03399799), and MagnetisMM-3 (Nct04649359) did not report on SPM outcomes [8,30,31].”
Chalopin, T., Cellerin, E., Demarquette, H., Pieragostini, A., Sonntag, C., Jaquet, C., de Wyngaert, Z. V., Rumpler, A., Roussel, M., Labouré, G., et al. (2025) · Blood Cancer Journal · doi:10.1038/s41408-025-01365-y · Cited by 2
“Teclistamab achieved an ORR of 63% and a median progression-free survival (PFS) of 11.3 months in MajesTec-1 trial [5, 6].”
InfluentialYi, J. H., Yoon, D. H., & Kım, K. (2025) · Seminars in Hematology · doi:10.1053/j.seminhematol.2025.11.003 · Cited by 2
Giles, H. V., & Kishore, B. (2026) · Antibodies · doi:10.3390/antib15010005 · Cited by 2
“A CT or MRI head should be performed in all patients with ICANS grade ≥ 2 to exclude cerebral edema or other acute abnormalities, such as a bleed, and an EEG should be performed.”
Que retenir dans la prise en charge des cancers en 2022 ?
Bay, J., Bouleuc, C., Caux, C., Delom, F., Firmin, N., Gandemer, V., L’Allemain, G., Magné, N., Orbach, D. H., Robert, J., et al. (2022) · Bulletin du Cancer · doi:10.1016/j.bulcan.2022.12.002 · Cited by 2
Suzuki, T., Kusumoto, S., Kamezaki, Y., et al. (2023) · Cancer Medicine · doi:10.1002/cam4.5996 · Cited by 2
Embracing Myeloma Chimeric Antigen Receptor-T: From Scientific Design to Clinical Impact
Hosoya, H., Rodríguez‐Otero, P., Sidana, S., & Borrello, I. (2023) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_389860 · Cited by 2
Self-citationTECLISTAMAB-ASSOCIATED SCLEROUVEITIS WITH HYPOPYON
Liu, T., Schwartz, T. D., Chebolu, A. P., et al. (2023) · Retinal Cases & Brief Reports · doi:10.1097/icb.0000000000001449 · Cited by 2
Chimeric Antigen Receptor T Cells in Multiple Myeloma
Shah, P., & Sperling, A. S. (2023) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2023.05.008 · Cited by 1
Immunotherapy for multiple myeloma: new chances and hope
Xu, J., An, G., & Qiu, L. (2023) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2023.0258 · Cited by 1
“Teclistamab has shown a high rate of deep and durable response in RRMM, with an ORR of 63.0% and a rate of complete remission or better ( ≥ CR) of 39.4% in the MajesTEC-1 trial 13 .”
BackgroundInfluentialSingle-agent belantamab mafodotin in patients with relapsed or refractory multiple myeloma.
Rodríguez-Otero, P., Tamariz, L. E., & San-Miguel, J. (2023) · The Lancet Haematology · doi:10.1016/s2352-3026(23)00278-8 · Cited by 1
Self-citationGubler, K. D., Sieracki, M. T., Merklin, K. W., & Stephenson, L. G. (2023) · Side effects of drugs annual · doi:10.1016/bs.seda.2023.09.011 · Cited by 3
Metadata
- Authors
- Moreau, P., Garfall, A. L., van de Donk, N. W. C. J., Nahi, H., San-Miguel, J. F., Oriol, A., Nooka, A. K., Martin, T., Rosinol, L., Chari, A., Karlin, L., Benboubker, L., Mateos, M.-V., Bahlis, N., Popat, R., Besemer, B., Martínez-López, J., Sidana, S., Delforge, M., Pei, L., Trancucci, D., Verona, R., Girgis, S., Lin, S. X. W., Olyslager, Y., Jaffe, M., Uhlar, C., Stephenson, T., Van Rampelbergh, R., Banerjee, A., Goldberg, J. D., Kobos, R., Krishnan, A., & Usmani, S. Z.
- Affiliations
- Karolinska University Hospital (SE)
- From the Hematology Clinic, University Hospital Hôtel-Dieu, Nantes (P.M.), Service d’Hématologie Clinique, Centre Hospitalier Lyon Sud, Pierre-Bénite (L.K.), and Service d’Hématologie et Thérapie Cellulaire, Hôpital Bretonneau, Centre Hospitalier Régional Universitaire, Tours (L.B.) — all in France; Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia (A.L.G.), and Janssen Research and Development, Spring House (R.V., S.G., S.X.W.L., C.U., T.S., A.B.) — both in Pennsylvania; the Department of Hematology, Amsterdam University Medical Center, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, Amsterdam (N.W.C.J.D.); Karolinska University Hospital at Huddinge, Stockholm (H.N.); Clínica Universidad de Navarra, Centro de Investigación Médica Aplicada, Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Instituto de Investigación Sanitaria de Navarra, Pamplona (J.F.S.-M.), Institut Català d’Oncologia and Institut Josep Carreras, Hospital Germans Trias i Puj...
- City Of Hope National Medical Center (US)
- Memorial Sloan Kettering Cancer Center (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2022-08-11
- Volume
- 387
- Issue
- 6
- Pages
- 495-505
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC10587778
- OpenAlex
- W4282033105
- Cited by
- 1,269
- References
- 25
- Citations by year
- 2026: 335 · 2025: 341 · 2024: 320 · 2023: 231 · 2022: 39
- FWCI
- 169.47
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion)
- PubMed Central (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Lirias (submittedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Funders
- Janssen Research & Development, LLC
- Topics
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Keywords
- teclistamab, relapsed/refractory multiple myeloma, bispecific T-cell engagers, overall response rate, minimal residual disease negativity, progression-free survival, cytokine release syndrome, neurotoxicity, dose-limiting toxicity, subcutaneous administration, immunotherapy safety and efficacy
- MeSH terms
- Antineoplastic Agents, Immunological, Antineoplastic Agents, Antineoplastic Combined Chemotherapy Protocols, Humans, Injections, Subcutaneous, Multiple Myeloma, Neoplasm Recurrence, Local, Recurrence, T-Lymphocytes, CD3 Complex, Antibodies, Bispecific, B-Cell Maturation Antigen, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-12, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-12 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
